NCT02296996View on ClinicalTrials.gov

Dabrafenib and Trametinib for BRAF-inhibitor Pretreated Patients

PHASE2CompletedINTERVENTIONAL
Enrollment

25

Participants

Timeline

Start Date

October 31, 2014

Primary Completion Date

December 31, 2017

Study Completion Date

December 31, 2017

Conditions
Malignant Melanoma
Interventions
DRUG

Dabrafenib + Trametinib

Trial Locations (1)

1090

UZ Brussel, Brussels

All Listed Sponsors
lead

Universitair Ziekenhuis Brussel

OTHER

NCT02296996 - Dabrafenib and Trametinib for BRAF-inhibitor Pretreated Patients | Biotech Hunter | Biotech Hunter